Výsledky vyhledávání - "J A, Gebhart"

Review

Method and Measurement of Health Education C. G. Payne J. C. Gebhart

Autor: McCracken, C. C.

Publikováno v: The Journal of Educational Research, 1927 Mar 01. 15(3), 224-225.

Externí odkaz: https://www.jstor.org/stable/27523455

Tables S1-S12, Figure S1-S3 from Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Autor: Mitch Dowsett, Martine J. Piccart-Gebhart, Brian Leyland-Jones, Dimitrios Zardavas, Phuong Dinh, Richard D. Gelber, Kathleen I. Prichard, Nadia Harbeck, Masakazu Toi, Giuseppe Viale, Federico Rojo, Denis Larsimont, Evandro de Azambuja, Astrid Kiermaier, Margaret Hills, Varvara Polydoropoulou, Michael Gnant, Urania Dafni, Martin Filipits

Table S1: Summary of baseline characteristics for the current analysis cohort vs. the Remainder of HERA patients Table S2: Summary of Disease-free Survival by subgroup of patients Table S3: Summary of Overall Survival by subgroup of patients Table S4

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7444b3192f76c71c3908c1c5cead8b75
https://doi.org/10.1158/1078-0432.22469921.v1

Zobrazit plný text záznamu

Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial

Autor: Carmine De Angelis, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Lieveke Ameye, Marianne Paesmans, Sarra El-Abed, Anup Choudhury, Sylvia Napoleone, Saranya Chumsri, Martine J. Piccart-Gebhart, Alvaro Moreno-Aspitia, Henry Leonidas Gomez, Giuseppe Viale, Susan G. Hilsenbeck, Mothaffar F. Rimawi, C. Kent Osborne, Evandro de Azambuja, Rachel Schiff

Publikováno v: Journal of Clinical Oncology. 40:522-522

522 Background: Our preclinical findings suggest a role for the mevalonate pathway (MVA) in treatment resistance in HER2+ BC by providing alternative growth and survival signaling to bypass potent HER2 blockade, which could be overcome by the MVA inh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b53c03ec63c22920f440593f84007df
https://doi.org/10.1200/jco.2022.40.16_suppl.522

Zobrazit plný text záznamu

Demographic and laboratory determinants of humoral immune responses and impact of different anti-SARS-CoV-2 vaccine platforms in patients with cancer: A systematic review and meta-analysis

Autor: Diogo Martins-Branco, Angela Loizidou, Guilherme Nader Marta, Ana Tecic Vuger, Veronique Debien, Lieveke Ameye, Mariana Brandão, Kevin Punie, Chloe Spilleboudt, Karen Willard-Gallo, Ahmad Awada, Martine J. Piccart-Gebhart, Evandro de Azambuja

Publikováno v: Journal of Clinical Oncology. 40:1543-1543

1543 Background: Patients (pts) with cancer have increased mortality from COVID-19 and their vaccination is crucial to prevent severe infection. We aimed to identify demographic and laboratory determinants of humoral immune responses to COVID-19 vacc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2168cad7ad4e5ad5268b6b2c4f72e45e
https://doi.org/10.1200/jco.2022.40.16_suppl.1543

Zobrazit plný text záznamu

Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study

Autor: Aditya Bardia, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Adam Brufsky, Kevin Kalinsky, Javier Cortes, Joyce O'Shaughnessy, Veronique C Dieras, Lisa A. Carey, Luca Gianni, Martine J. Piccart-Gebhart, Sibylle Loibl, Yanni Zhu, See-Chun Phan, Sara A. Hurvitz

Publikováno v: Journal of Clinical Oncology. 40:1071-1071

1071 Background: Treatment goals for pts with metastatic breast cancer include extended survival and improved quality of life (QoL). SG is an antibody-drug conjugate composed of an anti–Trop-2 antibody coupled to the cytotoxic SN-38 payload via a p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::677a81b2dea812d5a023b1ea38460e45
https://doi.org/10.1200/jco.2022.40.16_suppl.1071

Zobrazit plný text záznamu

Impact of cancer diagnosis, stage, and systemic therapies on immunogenicity after COVID-19 vaccination in patients with cancer: A systematic review and meta-analysis

Autor: Guilherme Nader Marta, Chloe Spilleboudt, Diogo Martins-Branco, Ana Tecic Vuger, Veronique Debien, Lieveke Ameye, Mariana Brandão, Kevin Punie, Angela Loizidou, Karen Willard-Gallo, Ahmad Awada, Martine J. Piccart-Gebhart, Evandro de Azambuja

Publikováno v: Journal of Clinical Oncology. 40:1537-1537

1537 Background: Patients (pts) with cancer are at increased risk of severe COVID-19. Both underlying malignancy and anti-cancer treatments influence the immune system, potentially impacting the level of vaccine protection achieved. Methods: A system

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1330d3383e422ff158a59592f16939c4
https://doi.org/10.1200/jco.2022.40.16_suppl.1537

Zobrazit plný text záznamu

DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade

Autor: Veronique Debien, Virginie ADAM, Rafael Caparica, Debora Fumagalli, Chloé Velghe, Julie Gaye, Vanessa Correia De Nobrega, Amal Arahmani, Gabriele Zoppoli, Martine J. Piccart-Gebhart

Publikováno v: Journal of Clinical Oncology. 40:TPS621-TPS621

TPS621 Background: Human Epidermal growth factor Receptor-2 positive (HER2+) breast cancer (BC) heterogeneity can be captured at the mRNA level by the PAM50 classification. The HER2 “Enriched” (HER2-E) intrinsic subtype is encountered more often

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8086e5418888a60c713c10fa937dcdb
https://doi.org/10.1200/jco.2022.40.16_suppl.tps621

Zobrazit plný text záznamu

Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial

Publikováno v: Journal of Clinical Oncology. 40:12084-12084

12084 Background: The potential gonadotoxicity of anti-HER2 agents remains largely unknown and limited conflicting evidence exists for taxanes. Anti-Mullerian hormone (AMH) is an established biomarker of ovarian reserve; its measurement during system

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dd80cb00f7acdab99c534a9636dfff6e
https://doi.org/10.1200/jco.2022.40.16_suppl.12084

Zobrazit plný text záznamu